Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Omar O Abudayyeh · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $664,371 — Project Summary Despite extraordinary advances in genome engineering, tools for precise and efficient gene correction across all cell types and desired edits remain lacking. Current programmable DNA cleavage tools, such as CRISPR-Cas9, rely on cellular DNA repair mechanisms, which are inefficient an…
Peter Fekkes · UBIQUITX, INC. · 2024 · $299,921 — Abstract UbiquiTx is developing a programmable, modular therapeutic platform for the direct modification of proteins of interest (POIs). Leveraging advances in artificial intelligence, protein engineering, and mRNA as a therapeutic modality, this platform allows for the engineering of enzymes to pre…
Dewan Syed Fahmeed Hyder · YALE UNIVERSITY · 2024 · $209,375 — Project Summary Stroke is the leading cause of disability in the United States. Despite the effectiveness of thrombolysis and thrombectomy, outcomes after stroke remain poor and effective cerebroprotectant therapies are needed. This project will leverage the complementary expertise of a Stroke Neuro…
Ram I. Mahato · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2024 · $390,632 — PROJECT SUMMARY Liver injury from alcohol abuse, and obesity can lead to liver inflammation, steatosis, and fibrosis. Liver cell damage results in the release of inflammatory cytokines from hepatocytes and Kupffer cells (KCs), which cause the activation of hepatic stellate cells (HSCs). If unresolv…
Aaron Clifford Brown · MAINEHEALTH · 2024 · $412,800 — Project Summary/Abstract The obesity epidemic is a global public health issue, that leads to an increased risk for type 2 diabetes and cardiovascular disease. Hypertrophy, inflammation, and excess lipid accumulation in white adipocytes within fat tissue are hallmarks of obesity that contribute to me…
Jennifer Eileen Adair · FRED HUTCHINSON CANCER CENTER · 2024 · $895,395 — PROJECT SUMMARY / ABSTRACT The quest for an HIV cure remains incomplete, nearly half a century since the onset of the epidemic. Antiretroviral drug cocktails can suppress HIV infection, but suffer in their success owing to side effects and limitations in access and compliance. Injection of broadly n…
Renee Nicole Cottle · CLEMSON UNIVERSITY · 2024 · $591,640 — PROJECT SUMMARY Familial hypercholesterolemia (FH) affects 1 in 250 people and is characterized by impaired low-density lipoprotein (LDL) metabolism resulting in premature cardiovascular disease. CRISPR-Cas9-induced loss of function mutations in the gene encoding Angiopoietin-like 3 (ANGPTL3) has be…
Nicholas Oliver Fischer · UNIVERSITY OF CALIFORNIA AT DAVIS · 2024 · $212,201 — 19F MRI, has shown promising success in clinical trials for monitoring cell therapy, where small groups of cells, showing poor contrast in 1H-MRI (Magnetic Resonance Imaging), are easily tracked using 19F-MRI.1 Contrast is provided by nanoemulsions of perfluorocarbon (PFC) oils pre-loaded into cells…
Eric T Wang · UNIVERSITY OF FLORIDA · 2024 · $531,109 — Gene editing is moving towards the clinic, but several challenges must be addressed in order for it to be applied to skeletal muscle disease. Adeno-associated virus (AAV) is one of the most promising technologies to enable delivery of gene editing machinery to skeletal muscle, but at least four majo…
Yupeng Chen · UNIVERSITY OF CONNECTICUT STORRS · 2024 · $424,451 — Abstract The overall goal of this proposal is to develop novel biomaterials for intracellular therapeutics delivery. While messenger RNAs (mRNAs) are recognized as promising candidates for RNA therapeutics (such as anti- inflammatory drugs) as well as research tools (such as delivering Cas9 mRNA fo…
CRAIG J. MCCLAIN · UNIVERSITY OF LOUISVILLE · 2024 · $1,357,495 — The University of Louisville Alcohol Research Center (ULARC) was created to serve as a regional/national resource to perform interdisciplinary collaborative research on the role of nutrition as a cofactor in alcohol induced organ injury and as a possible therapeutic intervention to prevent/treat thi…
ROBERT M LAVKER · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $2,666,779 — Northwestern University (NU) is recognized for its strong interdisciplinary cutaneous, ocular, nanotechnology and immunology research programs with particular strength in investigations related to wound repair and inflammation. Leveraging these strengths, the theme of the NU CounterAct Center of Exc…
Vatche Agopian · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 · $628,431 — PROJECT SUMMARY Hepatocellular carcinoma (HCC) accounts for 80-85% of primary liver cancers, and mainly occurs in patients with liver cirrhosis or chronic hepatitis B virus (HBV) infection. Prognosis of HCC is dismal primarily due to advanced stage of disease at diagnosis. Current clinical practice …
WENKE FENG · TULANE UNIVERSITY OF LOUISIANA · 2024 · $520,062 — Numerous studies have reported the efficacy of probiotics for alcohol associated liver disease (ALD). This reflects a strong interest among the scientific and medical communities in identifying alternative or adjunctive approaches for ALD, for which there is no current effective or widely accepted t…
Fang-Yi Su · GEORGIA INSTITUTE OF TECHNOLOGY · 2024 · $110,905 — Engineered T cells that express chimeric antigen receptors (CARs) have shown remarkable efficacy against hematological malignancies. However, broad implementation of CAR T cell therapies is limited by the lengthy (3–5 weeks) and costly ($350K–450K per treatment) ex vivo manufacturing pipeline. This …
Giacomo Vacca · KINETIC RIVER CORPORATION · 2024 · $356,497 — PROJECT SUMMARY Extracellular vesicles (EVs) are small, lipid bound vesicles that are secreted by cells. Originally thought to serve little purpose, EVs have been gaining significant interest due to their promise as therapeutics for a wide range of indications including skin repair in wound healing …
BIN GUO · OHIO STATE UNIVERSITY · 2024 · $497,002 — PROJECT SUMMARY Targeted nanotechnologies have shown great promise in overcoming roadblocks in cancer therapeutics. Tumor metastasis has a limited response or resistance to chemotherapeutics and a moderate response to new antibody therapies. Our RNA nanotechnology has shown great promise in targeti…
David G. Keener · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $33,740 — PROJECT SUMMARY Infants with Rett syndrome (Rett) are born with loss-of-function mutations in the gene encoding MeCP2, a global regulator of gene expression. MeCP2 dysfunction in the brain severely affects neurons, leading to developmental deficits of varying severity that manifest after 6 months of…
Qianben Wang · DUKE UNIVERSITY · 2024 · $516,712 — Project Summary/Abstract Patients with lethal castration-resistant prostate cancer (CRPC) are currently treated with agents targeting androgen receptor (AR) signaling. However, AR inhibition has not dramatically improved CRPC patient survival, underscoring the need to discover novel oncogenic mechan…
Efstathios Karathanasis · CASE WESTERN RESERVE UNIVERSITY · 2024 · $570,868 — PROJECT SUMMARY: Cancer immunotherapy is based on the premise of immune-recognition and targeted killing of tumor cells, thus possesses the promising power to eradicate aggressive disease. Notably to date, immunotherapy with immune checkpoint inhibitors significantly prolongs the survival of patient…